alexa Liposomal 1,25-dihydroxyvitamin D3-3and#946;-bromoacetate is a Stronger Growth-inhibiting Agent than its un-encapsulated Counterpart in Prostate Cancer Cells

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Liposomal 1,25-dihydroxyvitamin D3-3β-bromoacetate is a Stronger Growth-inhibiting Agent than its un-encapsulated Counterpart in Prostate Cancer Cells

Encapsulating cytotoxic drugs in liposomal vehicles allows for the targeting of tumors while protecting the drugs from premature degradation. 1,25-Dihydroxyvitamin D3-3?-bromoacetate (1,25(OH)2D3-3-BE), a vitamin D receptor-alkylating agent inhibits the growth of prostate cancer cells. The aim of the study was to evaluate the efficacy of a liposomal preparation of 1,25(OH)2D3-3-BE versus 1,25(OH)2D3-3-BE in modulating the growth of prostate cancer cells. Results demonstrate that liposomal 1,25(OH)2D3-3-BE is significantly better than 1,25(OH)2D3-3-BE in inhibiting the growth. In addition, liposomal 1,25(OH)2D3-3-BE was found to be stable in human serum. Taken together, results of the studies delineated here suggest a therapeutic potential of liposomal 1,25(OH)2D3-3-BE in prostate cancer.

 

Citation: Persons KS, Hareesh S, Eddy VJ, Ray R (2010) Liposomal 1,25-dihydroxyvitamin D3-3β-bromoacetate is a Stronger Growth-inhibiting Agent than its un-encapsulated Counterpart in Prostate Cancer Cells. J Steroids Hormon Sci 1:101. doi: 10.4172/2157-7536.1000101

 
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger